Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
100%(6 trials)
Terminated
4(33%)

Phase Distribution

Ph phase_3
3
25%
Ph phase_1
6
50%
Ph phase_2
2
17%

Phase Distribution

6

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(5)
Other(1)

Detailed Status

Completed6
Terminated4
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 22 (18.2%)
Phase 33 (27.3%)

Trials by Status

unknown18%
terminated433%
completed650%
withdrawn18%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT03000257Phase 1

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Completed
NCT03086239Phase 1

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Completed
NCT02674568Phase 2

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Completed
NCT03033511Phase 3

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Terminated
NCT03061812Phase 3

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

Completed
NCT03543358Phase 2

A Long-Term Study of Rovalpituzumab Tesirine

Completed
NCT02709889Phase 1

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Terminated
NCT03026166Phase 1

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Terminated
NCT02819999Phase 1

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Terminated
NCT03503890

Expanded Access to Rovalpituzumab Tesirine

Unknown
NCT03334487Phase 3

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Withdrawn
NCT02874664Phase 1

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12